Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis

por Yoshida, Shunsuke, Saito, Tomohiro, Shibagaki, Keigo, Hirao, Keiichi, Yuza, Takatoshi, Tomosugi, Naohisa, Honda, Hirokazu
Publicado 2023

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis

por Honda, Hirokazu, Kobayashi, Yasuna, Onuma, Shoko, Shibagaki, Keigo, Yuza, Toshitaka, Hirao, Keiichi, Yamamoto, Toshinori, Tomosugi, Naohisa, Shibata, Takanori
Publicado 2016

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis

por Honda, Hirokazu, Tanaka, Kenji, Michihata, Tetsuo, Shibagaki, Keigo, Yuza, Toshitaka, Hirao, Keiichi, Tomosugi, Naohisa, Ganz, Tomas, Higashimoto, Yuichiro
Publicado 2020